ZyVersa Therapeutics, Inc.
ZVSA
$0.6794
-$0.0306-4.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -30.64% | -34.38% | -41.55% | -32.59% | 7.89% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -33.19% | -36.64% | -46.01% | -44.01% | -15.95% |
| Operating Income | 33.19% | 36.64% | 46.01% | 44.01% | 15.95% |
| Income Before Tax | 91.66% | 91.27% | 77.92% | 77.59% | -574.65% |
| Income Tax Expenses | 100.08% | 100.07% | 93.89% | 93.89% | -369.19% |
| Earnings from Continuing Operations | 90.94% | 90.42% | 76.20% | 75.86% | -601.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 90.94% | 90.42% | 76.20% | 75.86% | -601.11% |
| EBIT | 33.19% | 36.64% | 46.01% | 44.01% | 15.95% |
| EBITDA | 33.18% | 36.64% | 46.03% | 44.03% | 15.96% |
| EPS Basic | 99.60% | 99.43% | 96.11% | 95.05% | -392.84% |
| Normalized Basic EPS | 95.01% | 96.52% | 93.96% | 86.10% | 44.47% |
| EPS Diluted | 99.60% | 99.43% | 96.11% | 95.05% | -392.84% |
| Normalized Diluted EPS | 95.01% | 96.52% | 93.96% | 86.10% | 44.47% |
| Average Basic Shares Outstanding | 601.41% | 1,040.05% | -97.10% | -98.07% | -98.92% |
| Average Diluted Shares Outstanding | 601.41% | 1,040.05% | -97.10% | -98.07% | -98.92% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |